Patients Divided Over Alzheimerâs Drug: Is It a âRisk Iâm Willing to Takeâ or Just a âMagic Pillâ?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimerâs disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.